Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902576 · ClinicalTrials.gov registry record
Chronic GVHD Response Measures Validation
A clinical trial of Graft Vs Host Disease, sponsored by Fred Hutchinson Cancer Center.
- Active
- Registry status
- 383
- Enrollment target
- 1
- Study location
NCT01902576 is a study of Graft Vs Host Disease that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 383 participants, above the 127-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (202% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01902576, a study of Graft Vs Host Disease, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 383 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop and validate endpoint measures that can accurately determine whether patients are responding to treatment for chronic Graft-versus-Host Disease (GVHD). Hopefully, this will also lead to being better able to predict which patients will respond to what therapies.
Conditions Studied
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2013-06 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01902576
The ClinicalTrials.gov registry entry for NCT01902576 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 127-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (202% higher). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01902576 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01902576 about?
NCT01902576 is a clinical study titled "Chronic GVHD Response Measures Validation". The purpose of this study is to develop and validate endpoint measures that can accurately determine whether patients are responding to treatment for chronic Graft-versus-Host Disease (GVHD). Hopefully, this will also lead to being better able to predict which patients will respond to what therapies...
What is the current status of trial NCT01902576?
This trial is currently active not recruiting. The enrollment target is 383 participants. The study started on 2013-06. Estimated completion is 2027-02.
What conditions does trial NCT01902576 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
Who is sponsoring clinical trial NCT01902576?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01902576 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
RECRUITING
-
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
RECRUITING · NA
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.